"There’s nothing more motivating than successfully reducing great new scientific discoveries to actual practice: making new medical products with the potential to transform clinical outcomes – that’s ultimately what the life science industry and a firm like Pappas is all about."

Peter is an experienced life science industry consultant and has been an executive-in-residence with Pappas Ventures since 2012. He leads the firm’s initiatives in translational medicine and is the Program Manager for the Wake Forest Technology Development Program. He also provides business development and due diligence support to the firm’s venture funds and portfolio companies.

Peter has thirty-five years of experience in the pharmaceutical and biotech industry, spanning all areas of the business from sales representative to country-level general manager and CEO; and companies ranging from multinationals like Abbott and Glaxo to start-up biotechs. As Vice President and Therapy Area Head at Glaxo Wellcome in the mid-1990s, he led the global introduction of combination HIV therapy that revolutionized HIV treatment and quintupled Glaxo’s global HIV portfolio sales, while keying industry leadership on global treatment access. Peter has since served as CEO of two private start-up enterprises, a viral vector vaccine company that raised over $80 million in NIH HIV and biodefense vaccine grants, and a specialty pharmaceutical company he led to an exit via a strategic transaction.

Peter currently serves on the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research, and is a member of the Long Island Bioscience Hub External Review Board. He was a past member of the BIO board, past Chairman of the North Carolina Biosciences Organization (NCBIO), and was a director of Memory Pharmaceuticals from 2004 until its sale to Roche in 2009. He has lived and worked in the US, Greece, the Middle East, Puerto Rico, New Zealand, and London.

Education:

Indiana University (BA, History)
IU Kelley School of Business (MBA)